IP Library Patent Application 12089169
Patent Application
App. No. 12/089,169

Combination Therapy Comprising Substituted Oxazolidinones for the Prevention and Treatment of Cerebral Circulatory Disorders

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/089,169
Abstract

The present invention relates to combinations of A) oxazolidinones of the formula (I), with B) antiarrhythmics, processes for the production of these combinations, their use for the prophylaxis and/or treatment of diseases, and their use for the manufacture of medicaments for the prophylaxis and/or treatment of diseases, especially of thromboembolic disorders and/or complications.

Claims (26)

1 - 10 . (canceled)

11 . A combination comprising

A) a compound of the formula (I)

in which

R 1 is 2-thiophene which is substituted in position 5 by a radical from the group of chlorine, bromine, methyl or trifluoromethyl,

R 2 is D-A-:

where:

the radical “A” is phenylene;

the radical “D” is a saturated 5- or 6-membered heterocycle which is linked via a nitrogen atom to “A”,

which has a carbonyl group in direct vicinity to the linking nitrogen atom, and in which a ring carbon member may be replaced by a heteroatom from the series S, N and O;

where

the group “A” defined above may optionally be substituted once or twice in the meta position relative to the linkage to the oxazolidinone by a radical from the group of fluorine, chlorine, nitro, amino, trifluoromethyl, methyl or cyano,

R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are hydrogen,

or one of the salts, solvates and solvates of the salts thereof and

B) an antiarrhythmic.

12 . The combination of claim 11 , wherein the compound of the formula (I) is 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide of the formula

or one of the salts, solvates and solvates of the salts thereof.

13 . The combination of claim 11 , wherein the antiarrhythmic is an adenosine A1 agonist.

14 . The combination of claim 11 , wherein the antiarrhythmic is 2-amino-6-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}sulfanyl)-4-[4-(2-hydroxyethoxy)phenyl]-3,5-pyridinedicarbonitrile of the formula

or one of the salts, solvates and solvates of the salts thereof.

15 . A process for producing the combination of claim 11 , wherein one or more oxazolidinones of the formula (I) and one or more antiarrhythmics are combined or prepared in any suitable way.

16 . A method for the prophylaxis and/or treatment of a thromboembolic disorder comprising administering a therapeutically effective amount of the combination of claim 11 to a patient in need thereof.

17 . A medicament comprising at least one combination as claimed in claim 11 and a further active pharmaceutical ingredient.

18 . A medicament comprising at least one combination as claimed in claim 11 and one or more pharmacologically acceptable excipients and/or carriers.

19 . A method for the prophylaxis and/or treatment of a thromboembolic disorder comprising administering a therapeutically effective amount of the medicament of claim 18 to a patient in need thereof.

20 . A method for the prevention or treatment of cardiogenic thromboembolisms and the prevention, reduction or termination of arrhythmias comprising administering a therapeutically effective amount of the medicament of claim 18 to a patient in need thereof.

Assignments (3)
CORRECTION IN COVER SHEET PREVIOUSLY RECORDED Recorded Apr 21, 2009
From: BAYER HEALTHCARE AG
To: BAYER SCHERING PHARMA AG
Reel/Frame 022575/0337 →
MERGER Recorded Apr 8, 2009
From: BAYER HEALTHCARE AG
To: BAYER SCHERING PHARMA AG
Reel/Frame 022520/0150 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 7, 2008
From: PERZBORN, ELISABETH, DR.; KRAHN, THOMAS, DR.
To: BAYER HEALTHCARE AG
Reel/Frame 020914/0761 →